Development of 11β -HSD1 Inhibitors for the Treatment of Type 2 Diabetes

Author(s): Clarence Hale, Minghan Wang

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 8 , Issue 7 , 2008

Become EABM
Become Reviewer


Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11β- hydroxysteroid dehydrogenase type 1 (11β-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11β-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.

Keywords: 11β-hydroxysteroid dehydrogenase, glucocorticoid receptor, cortisol, ex vivo activity, insulin resistance, Cushing's syndrome

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [702 - 710]
Pages: 9
DOI: 10.2174/138955708784567421
Price: $65

Article Metrics

PDF: 6